Literature DB >> 32887553

Predictors of response to exposure and response prevention-based cognitive behavioral therapy for obsessive-compulsive disorder.

Sayo Hamatani1,2, Aki Tsuchiyagaito1,3, Masato Nihei1, Yuta Hayashi4,5, Tokiko Yoshida1, Jumpei Takahashi1, Sho Okawa5,6, Honami Arai1, Maki Nagaoka1, Kazuki Matsumoto1, Eiji Shimizu1,4,7, Yoshiyuki Hirano8.   

Abstract

BACKGROUND: Cognitive behavioral therapy (CBT), which includes exposure and response prevention (ERP), is effective in improving symptoms of obsessive-compulsive disorder (OCD). However, whether poor cognitive functions and autism spectrum disorder (ASD) traits affect the therapeutic response of patients with OCD to ERP-based CBT remains unclear. This study aimed to identify factors predictive of the therapeutic response of Japanese patients with OCD to ERP-based CBT.
METHODS: Forty-two Japanese outpatients with OCD were assessed using the Wechsler Adult Intelligence Scale-III (WAIS-III), Yale-Brown Obsessive-Compulsive Scale, Patient Health Questionnaire 9-item scale, and Autism Spectrum Quotient (AQ) at pre- and post-treatment. We used multiple regression analyses to estimate the effect on therapeutic response change. The treatment response change was set as a dependent variable in multiple regression analyses.
RESULTS: Multiple regression analyses showed that among independent variables, communication as an AQ sub-scale and Letter Number Sequencing as a WAIS-III sub-test predict the therapeutic response to ERP-based CBT .
CONCLUSIONS: Our results suggest that diminished working memory (Letter Number Sequencing), poor communication skill (AQ sub-scale) may undermine responsiveness to ERP-based CBT among patients with OCD. TRIAL REGISTRATION: UMIN, UMIN00024087 . Registered 20 September 2016 - Retrospectively registered (including retrospective data).

Entities:  

Keywords:  Cognitive behavioral therapy; Exposure and response prevention; Obsessive-compulsive disorder; Therapeutic response

Mesh:

Year:  2020        PMID: 32887553      PMCID: PMC7473813          DOI: 10.1186/s12888-020-02841-4

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


Background

Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by repeated compulsive and obsessive behavior, and its 12-month prevalence in the world is 1.1 to 1.8% (DSM-5) [1]. NICE guidelines recommend the use of CBT including exposure response prevention (ERP) as a first-line of treatment for OCD, and selective serotonin reuptake inhibitors (SSRI) or more intensive CBT including ERP or combined treatment (CBT including ERP plus SSRI) for moderate to severe OCD [2]. With a treatment response change of approximately 45 to 70% [2, 3], the efficacy of the CBT including ERP has been demonstrated [4-7]. However, about 20% of OCD don’t have good enough response to ERP [3]. Numerous studies have been conducted on cognitive functions of individuals to account for their lack of response to CBT including ERP [8-11]. Neuropsychological functioning has so far been studied as a predictor of the responsiveness of patients with OCD to CBT including ERP, but the results are inconsistent [8-11]. Predictor variables of CBT including ERP for OCD can be classified into various categories [12]: demographic variables; OCD symptom characteristics such as severity; comorbidities and associated symptom severity; cognitive influences; motivational factors such as treatment expectations; treatment factors such as compliance and therapeutic alliance; biological factors; other factors such as personality, family dysfunction, and treatment-specific characteristic [12, 13]. Previous studies have suggested that responses to CBT including ERP are diminished among patients whose symptoms overlap with autism spectrum disorder (ASD) criteria [14, 15]; treatment resistance may thus be attributable the presentation of ASD characteristics. Moreover, severe major depressive disorder has been shown to inhibit therapeutic response to CBT including ERP [12]. It has also been suggested that the severity of obsessive-compulsive symptoms and beliefs may influence the response to CBT including ERP treatment [16]. Conversely, several previous studies have reported that comorbidities such as depression and anxiety do not affect treatment responsiveness to CBT including ERP [17-19]. Therefore, the results are inconsistent [12-19], and further research is needed to identify predictors of response to CBT including ERP. Furthermore, no studies have examined the factors that affect treatment effects including the full-version of the WAIS for patients with OCD. Specifying people that need an adapted treatment strategy is very important, and it is necessary to specify predictors of treatment response. Here, the present study aimed to elucidate factors related to therapeutic responses to ERP-based CBT, focusing on ASD propensity, cognitive function, OCD severity, and depression severity.

Methods

Study design

The present study was included patients who visited the Cognitive Behavioral Therapy Center of Chiba University between March 2013 to May 2018; it included 106 patients who were diagnosed with OCD by a psychiatrist using the Structured Clinical Interview for DSM-IV Axis I Disorders [20]. At the time of the visit to our center, the patient was already diagnosed with OCD at another institution, and he/she brought a referral letter. The diagnosis and evaluation were performed by a well-educated psychiatrist and clinical psychologist at the IAPT of Chiba University. The exclusion criteria were any organic central nervous system disorder, psychosis, intellectual disability, high risk of suicide, substance abuse or dependence, or unstable medical condition; patients for whom cognitive function could not be measured in terms of outcomes and those who did not complete the ERP intervention were also excluded. A total of 64 patients were therefore excluded, so that eventually 42 patients (mean age = 33.2 years, standard deviation =7.6 years, female = 26, male = 16) with OCD were included in the analysis (Fig. 1). Moreover, none of the participants were diagnosed with attention deficit hyperactivity disorder. Nine patients were pharmacotherapy-free, and 33 patients were taking psychotropic drugs at the time of assessment [29 patients (SSRI), 2 patients (Noradrenergic and specific serotonergic antidepressant), 5 patients (Tricyclic antidepressant), 17 patients (Benzodiazepine), 6 patients (Dopamine system stabilizer), 2 patients (Dopamine serotonin antagonist), 1 patient (Serotonin-dopamine antagonist), 3 patients (Multi-acting receptor targeted antipsychotic), 2 patients (Benzamide antipsychotics), 2 patients (Branched fatty acid), and 1 patient (Butyrophenone)](See supplemental material).
Fig. 1

Patient flow

Patient flow

Intervention

ERP-based CBT was performed on patients with OCD according to a treatment manual created by our research group designed for adult outpatients with OCD(https://www.mhlw.go.jp/file/06-Seisakujouhou-12200000-Shakaiengokyokushougaihokenfukushibu/0000113840.pdf). The modules were derived from a previous study on in-person ERP for OCD in Japan [7]; these modules included psychoeducation, exposure exercises, and homework assignments [7]. Sixteen ERP-based CBT sessions of 50 min in length were scheduled each week. All therapists who participated in this study completed the Improving Access to Psychological Therapies project at Chiba University [21]. The quality of ERP-based CBT was controlled through weekly group supervisions led by a psychiatrist. It was recommended that the therapist should record the content of the session using videography and an integrated chip (IC) recorder. However, it was possible for the patient to refuse to consent to this recording.

Outcomes

Yale-Brown obsessive-compulsive scale

To assess the severity of the obsessive-compulsive symptoms, we used the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [22, 23]. This scale consists of 10 items (5 obsessions and 5 compulsive items). The questionnaire items are scored on a 4-point Likert-scale; with 0 = no symptoms to 4 = extreme symptoms. The total score range is 0–40, with individual subtotals for obsessions and severity of obsessions. This scale was used in a semi-structured interview setting.

Obsessive-compulsive inventory

The Obsessive-Compulsive Inventory (OCI) consists of 42 items and is a 5-point Likert-scale [24, 25]. It consists of seven subscales (washing, checking, doubting, ordering, obsessions, hoarding, and neutralizing).

Patient health Questionnaire-9

The presence and severity of symptoms of depression experienced in the previous 2 weeks were evaluated using the Patient Health Questionnaire-9 (PHQ-9) [26, 27]. The self-administered questionnaire items are scored on a 4-point Likert-scale; with 0 = not at all to 3 = almost every day. The total score range is 0–27 (0 to 4 indicates no symptoms, 5 to 9 indicates mild symptoms, 10 to 14 indicates moderate symptoms, 15 to 19 indicates moderate to severe symptoms, and 20 to 27 indicates severe symptoms). The cut-off score for clinically significant symptoms of depression is 10.

Generalized anxiety disorder − 7 (GAD-7)

The presence and severity of generalized anxiety disorder was assessed using the GAD-7 [28, 29], a self-administered questionnaire that assesses the severity of generalized anxiety disorder in the previous 2 weeks on a 4-point Likert scale; with 0 = not at all to 3 = almost every day. The total score range is 0–21 (0 to 4 indicates no symptoms, 5 to 9 indicates mild symptoms, 10 to 14 indicates moderate symptoms, and 15 to 21 indicates severe symptoms). The cut-off score for clinically significant symptoms of anxiety is 10.

Autism-spectrum quotient

Autism-spectrum Quotient (AQ) is a self-managed instrument that can use any of the dichotomous evaluations to measure autistic characteristics [30, 31]. The total score range is 0–50. It consists of five subscales (social skills, attention switching, attention to detail, communication, and imagination). The cut-off score for clinically significant symptoms of ASD is 33.

Wechsler adult intelligence scale-third edition

The Wechsler Adult Intelligence Scale-third edition (WAIS-III) is a comprehensive test of intellectual functioning [32, 33]. A total of 13 subtests assessing either verbal IQ (VIQ) or performance IQ (PIQ) were administered to patients with OCD. The subtests evaluating VIQ included Vocabulary, Similarities, Information, Comprehension, Arithmetic, Digit Span, and Letter-Number Sequencing; those assessing PIQ included Picture Completion, Block Design, Matrix Reasoning, Visual Puzzles, Digit Symbol Coding, and Symbol Search. The Object Assembly subtest was excluded from the present analysis because it has a lower confidence factor than the other subtests [34]. The aforementioned subtests were grouped into the following four indices: VCI (Vocabulary, Similarities, and Information), POI (Picture Completion, Block Design, Matrix Reasoning), WMI (Digit Span and Arithmetic, and Letter-Number Sequencing), and PSI (Symbol Search and Digit Symbol Coding).

Statistical analysis

The statistical analysis was performed using SPSS Statistics, version 26.00 (IBM Corp., Armonk, NY, USA). To investigate the predictive effects that patient pretreatment background may have had on the treatment response change post treatment, a series of analyses were performed. First, the treatment response change was obtained in terms of the difference between pre- and post-treatment Y-BOCS scores. Next, Pearson correlation coefficients were used to investigate the factors affecting the ERP-based CBT response change and to explore the relationships between such changes and other clinical variables including age, sex, severity of obsessive-compulsive symptoms in Y-BOCS at pretreatment, the traits associated with the autistic spectrum in AQ total scores or its sub-scales, intelligence index in WAIS-III or its sub-tests, OCI total score or its sub-scales, and severity of depression in PHQ-9. Finally, forward stepwise regression analysis was performed with the variables that remained significant in the correlation analysis as independent variables and the ERP-based CBT response change as the dependent variable. Moreover, the unpaired t-test was used to compare the ERP-based CBT plus pharmacotherapy group and ERP-based CBT without pharmacotherapy group, to investigate the effects of medication.

Results

Demographic and clinical characteristics and WAIS scores of patients with OCD are shown in Table 1. The correlations between the ERP-based CBT response change and other clinical variables in OCD group are presented in Table 2. Significant differences in the ERP-based CBT response change were observed according to sex (p = 0.017), Attention switching (p = 0.029), Communication (p = 0.026), and Letter Number Sequencing (p = 0.005). No significant correlation was found between the ERP-based CBT response change and any other clinical variable. Multiple regression analysis was performed with sex, communication, attention switching, and Letter Number Sequencing as explanatory variables and the ERP-based CBT response change as the dependent variable. Multiple regression analyses showed that communication as an AQ sub-scale and Letter Number Sequencing as a WAIS-III sub-test were significant predictors of ERP-based CBT response, if sex and attention switching were excluded for a better fit (Table 3). To investigate the effects of medication, the comparison of the treatment response of the ERP-based CBT plus pharmacotherapy group and ERP-based CBT without pharmacotherapy group did not reveal any significant differences (t (40) =0.876, p < 0.386).
Table 1

Characteristics and WAIS scores in patients with OCD

OCDN
Mean ± SD
No. (male/female)42 (16/26)
Age b33.19 ± 7.5542
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (pre) Total26.26 ± 4.1042
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (post) Total16.00 ± 8.1842
ERP-based CBT response change10.26 ± 7.8642
Obsessive Compulsive Inventory (OCI)
Washing18.59 ± 10.8139
Checking16.62 ± 9.1439
Doubting7.10 ± 4.0839
Ordering6.85 ± 4.6239
Obsessions14.26 ± 5.6139
Hoarding3.36 ± 3.1739
Neutralizing7.62 ± 5.0139
Total74.30 ± 26.1840
Patient Health Questionnaire-9 (PHQ-9)12.20 ± 5.8341
Generalized Anxiety Disorder −7 (GAD-7)11.93 ± 4.5140
Autism Spectrum Quotient (AQ) AQ
Social skill5.13 ± 2.6040
Attention switching6.20 ± 2.0440
Attention to detail5.32 ± 1.8240
Communication3.95 ± 2.6740
Imagination4.08 ± 2.3840
Total24.68 ± 7.7640
Wechsler Adult Intelligence Scale-III
Full-scale intelligence quotient (FSIQ)100.95 ± 10.9042
Verbal IQ102.43 ± 11.5142
Performance IQ98.88 ± 11.4042
Indices
 Verbal Comprehension Index (VCI)100.95 ± 11.7742
 Perceptual Organization Index (POI)100.45 ± 12.8642
 Working Memory Index (WMI)98.26 ± 16.3042
 Processing Speed Index (PSI)91.17 ± 17.1342
Subtests
Vocabulary10.52 ± 2.4442
Similarities10.55 ± 2.4742
Information9.38 ± 2.4742
Comprehension12.10 ± 2.9942
Arithmetic9.69 ± 2.6742
Digit Span10.99 ± 3.0642
Letter Number Sequencing9.86 ± 3.4342
Visual Puzzles10.48 ± 2.8042
Picture Completion9.67 ± 2.8142
Block Design9.67 ± 3.2142
Matrix Reasoning11.12 ± 2.6042
Digit Symbol Coding8.69 ± 2.9742
Symbol Search9.05 ± 2.6242
Table 2

Correlations between ERP-based CBT response change and other clinical indices in OCD

Nrp-value
Age420.120.455
Sexa420.37*0.017
Autism-Spectrum Questionnaire (AQ)
Social skill40−0.080.621
Attention switching40−0.35*0.029
Attention to detail400.070.674
Communication40−0.35*0.026
Imagination40−0.090.600
Total40−0.250.120
Y-BOCS (pre) Total420.180.249
Obsessive Compulsive Inventory (OCI)
Washing390.180.264
Checking39−0.230.161
Doubting39−0.170.295
Ordering390.000.994
Obsessions39−0.100.529
Hoarding39−0.220.186
Neutralizing39−0.060.726
Total40−0.090.562
PHQ-941−0.23-0.0260.142
GAD-740−0.1880.246
Full-scale intelligence quotient (FSIQ)420.080.621
WAIS-III Subtests
Vocabulary420.170.269
Similarities420.000.981
Information42−0.010.955
Comprehension420.050.740
Arithmetic420.130.431
Digit Span420.070.699
Letter Number Sequencing420.42**0.005
Visual Puzzles42−0.140.365
Picture Completion42−0.100.539
Block Design420.150.333
Matrix Reasoning42−0.130.418
Digit Symbol Coding420.210.178
Symbol Search420.040.792

*p < 0.01, **p < 0.05

Abbreviations: OCD obsessive-compulsive disorder, Y-BOCS Yale-Brown Obsessive-Compulsive Scale, PHQ-9 Patient Health Questionnaire-9, GAD-7 Generalized Anxiety Disorder-7

aFemale = 1. Male = 0

Table 3

Results of stepwise regression analyses on response to ERP-based CBT

Dependent variableIndependent variableAdjusted R2βp-value
ResponseCommunication0.33−0.44**0.002
Letter Number Sequencing0.50**0.001

**p < 0.01

Characteristics and WAIS scores in patients with OCD Correlations between ERP-based CBT response change and other clinical indices in OCD *p < 0.01, **p < 0.05 Abbreviations: OCD obsessive-compulsive disorder, Y-BOCS Yale-Brown Obsessive-Compulsive Scale, PHQ-9 Patient Health Questionnaire-9, GAD-7 Generalized Anxiety Disorder-7 aFemale = 1. Male = 0 Results of stepwise regression analyses on response to ERP-based CBT **p < 0.01

Discussion

The present study investigated whether clinical symptoms and cognitive functions are predictive of differential therapeutic response to ERP-based CBT among patients with OCD. We found that the ERP-based CBT response change was affected by diminished working memory as a Letter Number Sequencing and poor communication skill as an AQ subscale in Japanese participants with OCD. A retrospective study of randomized control trials assessing 108 obsessive-compulsive patients receiving selective serotonin reuptake inhibitors reported that co-morbidity affected treatment response [35]. Our results were not consistent with those of a previous study [35]. The results of the present study suggest that depressive mood severity was excluded, but that partial ASD propensity impairs treatment response. A previous review has suggested that CBT including ERP for obsessive-compulsive disorder with ASD is effective [36], but that the response to CBT including ERP is relatively poor [15]. The novelty of this study was that the ability to communicate in AQ predicted treatment response. Without good communication, it is difficult to set appropriate therapeutic goals and exposure tasks. Therefore, it is natural that communication disorder, one of the core disorders in ASD [1], impairs treatment response. The results of this study did not suggest that OCI’s sub-tests predict of response to ERP-based CBT. A subtype of obsessive-compulsive disorder, the hoarding state, was reported to reduce patient outcomes due to adherence [37]. Additionally, a previous study showed that reductions in obsessive beliefs influenced improvements in patients with OCD [38], which are inconsistent with the results of the present study. Previous studies suggested that patient consensus on therapeutic goals and tasks is probably also an important factor in implementing CBT including ERP [39, 40]. The present study did not measure patients’ adherence to ERP-based CBT or the degree of agreement on treatment. Future research should consider these as well. A previous representative study suggested that maleness was predictive of better treatment outcomes [41]. However, our results show that sex was not a predictor of the response to ERP-based CBT, and are consistent with some previous studies for children to adults [18, 42–44]. Although some authors have questioned whether Letter-Number Sequencing can accurately measure working memory [45], the results of the present study suggested that a subtest of working memory, “Letter Number Sequencing,” predicts treatment response. This suggests that the executive function, including working memory, of obsessive-compulsive patients undergoing ERP-based CBT may predict responsiveness. When patients with OCD have poor executive function, they might cannot understand their problem or conduct and complete ERP tasks appropriately. A previous brain imaging study showed that abnormalities in the left dorsolateral prefrontal cortex, a region that has been implicated in working memory [46], negatively affect CBT including ERP outcomes [15]. Mental flexibility, as measured using the California Verbal Learning Test, was predictive of a good response to CBT including ERP; in contrast, it was interesting to note that fluoxetine responsiveness was impaired [9]. Executive function weakness is also known to affect treatment response [9, 47–49]. The present study, for the first time in the world, has found that a WAIS-III full-version subtest, Letter Number Sequencing, predicts the response of ERP-based CBT treatment in patients with OCD. In other words, supplementing poor working memory may be beneficial for treatment and results of this study may be helpful to clinicians and cognitive behavioral practitioners choose more effective treatment strategy. In one example, to promote better responsiveness among patients with poor working memory, clinicians can provide more sessions and use visual aids during interventions [50]. Letter Number Sequencing is a simple test that can be performed in about 5 to 10 min. Therefore, clinicians and cognitive behavioral practitioners may be able to estimate response to treatment based on the results of WAIS-III Letter Number Sequencing and AQ communication score before conducting ERP-based CBT in patients with OCD. This study had several limitations. First, while our findings implicate ASD traits as a risk factor affecting the treatment response change, cohort studies for children and early adolescents have shown that OCD is predicted by beliefs such as intolerance to uncertainty [51]. Since patients with ASD are characterized by intolerance to uncertainty, it remains unclear whether ASD traits itself is a risk factor or whether the intolerance to uncertainty accounts for the lower responsiveness to ERP-based CBT. To clarify this point, it will be necessary to also use the Obsessive Belief Questionnaire in future investigations. Second, in this study, we found that the response of ERP-based CBT was not good when the AQ communication score was high. However, AQ is a self-administered scale, and it is unclear whether this accurately reflects the communication ability. Therefore, it is necessary to measure the quality of communication objectively by behavioral observation, and not by using a self-reported scale. In the future, a more detailed assessment, including the Second Edition of the Autism Diagnosis and Observation Schedule, will be needed to identify ASD [52]. Third, the effects of the participants’ medication were not included, because their administration might have changed according to their condition during ERP-based CBT, though we asked the physicians to maintain the medication content and dose constant as much as possible. Research that regulates the content of pharmacotherapy should be conducted in the future. Fourth, Y-BOCS evaluations were conducted by therapists who were in charge of the patients. Therefore, independent assessors would be needed to evaluate the primary outcomes, including Y-BOCS. Finally, we did not include patients who did not consent to ERP-based CBT in this study, because we could not obtain their post-treatment score (if they did not receive ERP-based CBT) or the reason for refusal.

Conclusions

Our results suggest that diminished working memory (Letter Number Sequencing), and poor communication skill (AQ sub-scale) score may undermine responsiveness to ERP-based CBT among patients with OCD. The corresponding predictors (working memory, communication skill) of response to ERP-based CBT explain 33% of the responsiveness to ERP-based CBT among patients with OCD. To validate our findings and overcome the limitations of this study, future research should also consider the intolerance to uncertainty and the quality of ERP-based CBT. Additional file 1. Pharmacotherapeutic agents used by the participants.
  38 in total

1.  [Development and use of the Japanese version of the self-report Yale-Brown Obsessive Compulsive Scale].

Authors:  S Hamagaki; S Takagi; Y Urushihara; Y Ishisaka; M Matsumoto
Journal:  Seishin Shinkeigaku Zasshi       Date:  1999

2.  Outcomes of cognitive behaviour therapy for obsessive-compulsive disorder in young people with and without autism spectrum disorders: A case controlled study.

Authors:  Kim Murray; Amita Jassi; David Mataix-Cols; Faye Barrow; Georgina Krebs
Journal:  Psychiatry Res       Date:  2015-03-18       Impact factor: 3.222

3.  NEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE-COMPULSIVE DISORDER.

Authors:  Daniela T Braga; Amitai Abramovitch; Leonardo F Fontenelle; Ygor A Ferrão; Juliana B Gomes; Analise S Vivan; Kimberly K Ecker; Cristiane F Bortoncello; Andrew Mittelman; Euripides C Miguel; Clarissa M Trentini; Aristides V Cordioli
Journal:  Depress Anxiety       Date:  2016-04-21       Impact factor: 6.505

Review 4.  Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators.

Authors:  Bunmi O Olatunji; Michelle L Davis; Mark B Powers; Jasper A J Smits
Journal:  J Psychiatr Res       Date:  2012-09-20       Impact factor: 4.791

5.  Effectiveness of Cognitive Behavioral Therapy for Individuals with Autism Spectrum Disorders and Comorbid Obsessive-Compulsive Disorder: A Review of the Research.

Authors:  Leman Kaniturk Kose; Lise Fox; Eric A Storch
Journal:  J Dev Phys Disabil       Date:  2017-07-29

6.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

7.  The Obsessive-Compulsive Inventory-Revised (OCI-R): validation of the German version in a sample of patients with OCD, anxiety disorders, and depressive disorders.

Authors:  Sascha Gönner; Rainer Leonhart; Willi Ecker
Journal:  J Anxiety Disord       Date:  2007-08-02

Review 8.  Clinical predictors of response to cognitive-behavioral therapy for obsessive-compulsive disorder.

Authors:  Mary L Keeley; Eric A Storch; Lisa J Merlo; Gary R Geffken
Journal:  Clin Psychol Rev       Date:  2007-04-29

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

10.  Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder with and without Autism Spectrum Disorder: Gray Matter Differences Associated with Poor Outcome.

Authors:  Aki Tsuchiyagaito; Yoshiyuki Hirano; Kenichi Asano; Fumiyo Oshima; Sawako Nagaoka; Yoshitake Takebayashi; Koji Matsumoto; Yoshitada Masuda; Masaomi Iyo; Eiji Shimizu; Akiko Nakagawa
Journal:  Front Psychiatry       Date:  2017-08-15       Impact factor: 4.157

View more
  4 in total

1.  Mindfulness-based psychotherapy in patients with obsessive-compulsive disorder: A meta-analytical Study.

Authors:  Antonio Riquelme-Marín; Ana Isabel Rosa-Alcázar; Juan Manuel Ortigosa-Quiles
Journal:  Int J Clin Health Psychol       Date:  2022-07-12

2.  Impact of the COVID-19 pandemic on exposure and response prevention outcomes in adults and youth with obsessive-compulsive disorder.

Authors:  Eric A Storch; Jessica C Sheu; Andrew G Guzick; Sophie C Schneider; Sandra L Cepeda; Bianca R Rombado; Rohit Gupta; Connor T Hoch; Wayne K Goodman
Journal:  Psychiatry Res       Date:  2020-11-26       Impact factor: 3.222

3.  Guided internet-based cognitive behavioral therapy for obsessive-compulsive disorder: A multicenter randomized controlled trial in Japan.

Authors:  Kazuki Matsumoto; Sayo Hamatani; Takuya Makino; Jumpei Takahashi; Futoshi Suzuki; Tomoko Ida; Shoko Hamamura; Shinichiro Takiguchi; Akemi Tomoda; Ichiro M Omori; Hirotaka Kosaka; Seina Shinno; Tomoki Ikai; Hiroyuki Hayashi; Hiroto Katayama; Yuki Shiko; Yoshihito Ozawa; Yohei Kawasaki; Chihiro Sutoh; Eiji Shimizu
Journal:  Internet Interv       Date:  2022-02-24

4.  Hypermethylation of the oxytocin receptor gene (OXTR) in obsessive-compulsive disorder: further evidence for a biomarker of disease and treatment response.

Authors:  Katharina Bey; Rafael Campos-Martin; Julia Klawohn; Benedikt Reuter; Rosa Grützmann; Anja Riesel; Michael Wagner; Alfredo Ramirez; Norbert Kathmann
Journal:  Epigenetics       Date:  2021-07-16       Impact factor: 4.861

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.